Additionally, it was found that the levels of TrkA and NGF in squamous cell carcinoma were upregulated, indicating that lung cancer drugs that target the NGF–TrkA pathway could be used for this disease (Figure 3) [102,103]. This evidence concerns the gene NTRK1 and squamous cell carcinoma.